FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to recombinant production of insulin analogue derivatives; it can be used in medicine for the treatment of diabetes.
EFFECT: invention provides for the production of insulin analogue derivatives, which have significantly increased half-life in vivo, and, thereby, can provide convenience to patients with diabetes, which injected insulin by themselves.
14 cl, 7 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCTION OF ACTIVE FORM OF LONG-ACTING INSULIN ANALOGUE DERIVATIVE, USING CLOSTRIPAIN | 2019 |
|
RU2781307C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| IMMTAC MOLECULES BINDING HLA-A*02 RESTRICTED PEPTIDE WITH INCREASED HALF-LIFE | 2020 |
|
RU2833530C2 |
| PROTEINS BINDING TO HEPCIDIN | 2011 |
|
RU2625011C2 |
| HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
| MUTEINS OF TEAR LIPOCALIN, POSSESSING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS OF OBTAINING THEM | 2009 |
|
RU2515063C9 |
| COMPOSITION AND USE OF ARGININE-DEPLETING AGENTS IN CANCER, OBESITY, METABOLIC DISORDERS AND RELATED COMPLICATIONS AND COMORBIDITIES | 2019 |
|
RU2826185C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
